<DOC>
	<DOCNO>NCT02590185</DOCNO>
	<brief_summary>Regarding direct cost social value depression , decision antidepressant treatment prescription must optimize much possible . The development personalize medicine psychiatry may reduce treatment failure , intolerance resistance , hence burden cost affective disorder . There hope biomarkers find guide treatment selection . It might decisive interest able assess individual 's metabolism activity . We propose explore relationship activity drug-metabolizing enzyme ( DME ) transporters- assess phenotypic approach efficacy antidepressant . We focus venlafaxine ( V ) provide reasonable second-step choice patient depression use extensively psychiatric practice , metabolism involve several cytochrome ( CYP ) P450 enzymes transporter P-gp . Thus , primary objective study study correlation concentration V metabolite ODesmethylV ( V+ODV ) drug metabolism variability assess phenotypic approach , patient major depressive disorder MADRS ≥ 20 despite 4 week V 150mg less</brief_summary>
	<brief_title>MetAbolism vaRiability VEnLafaxine</brief_title>
	<detailed_description />
	<mesh_term>Depressive Disorder</mesh_term>
	<mesh_term>Depression</mesh_term>
	<mesh_term>Depressive Disorder , Major</mesh_term>
	<mesh_term>Venlafaxine Hydrochloride</mesh_term>
	<criteria>Patient ( Hospitalized outpatient ) major depressive disorder MADRS ≥ 20 visit selection Patients non responder V 4 week V 150mg less Decision psychiatrist increase dose V visit selection Understanding French language able give write inform consent . Informed consent sign participate study Individuals cover social security regimen Patients treat one antidepressant Patients currently treat one drug substrate cocktail Sensitivity contraindication substrate drug use Current pregnancy , desire get pregnant , breastfeed Bipolar disorder schizophrenia</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>80 Years</maximum_age>
	<verification_date>September 2016</verification_date>
</DOC>